Importantly, by tracking the fate of labelled ECs following the cessation of CTLA4 blockade + LTβR agonist treatment, TA-HEVs were found to promptly transition back to a PCV state concomitant with a significant diminishment in CD3+ aggregates and tumour relapse [13]. This evidence concerns the gene LTBR and neoplasm.